Results 161 to 170 of about 83,002 (289)
Bioanalytical TERS and Advanced Data Processing Methods
Journal of Raman Spectroscopy, EarlyView.Tip‐enhanced Raman spectroscopy delivers label‐free, subnanometer vibrational imaging of biological systems. Recent advances in instrumentation, data analysis, and ambient/liquid operation enable surface‐selective mapping of molecular heterogeneity in proteins, nucleic acids, membranes, and viruses, positioning TERS as a powerful platform for nanoscale
Sarika Joshi +6 more
wiley +1 more source
Mass Spectrometry Structural Proteomics Enabled by Limited Proteolysis and Cross‐Linking
Mass Spectrometry Reviews, EarlyView.ABSTRACT The exploration of protein structure and function stands at the forefront of life science and represents an ever‐expanding focus in the development of proteomics. As mass spectrometry (MS) offers readout of protein conformational changes at both the protein and peptide levels, MS‐based structural proteomics is making significant strides in the
Haiyan Lu +4 more
wiley +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT Nitrooxidative stress, driven by excess reactive nitrogen species like peroxynitrite, contributes to the pathogenesis of many chronic diseases. Among its molecular footprints, 3‐nitrotyrosine (3NT) has emerged as a biologically relevant marker of protein nitration.
Brîndușa Alina Petre
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete +5 more
wiley +1 more source
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source
Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil +5 more
wiley +1 more source
Quantitative Assessment of Visible Nigrosome‐1 in Patients with Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background The nigrosome‐1 (N1) sign on susceptibility‐weighted imaging (SWI) typically disappears in Parkinson's disease (PD), though some patients can show uni−/bilaterally preserved N1. Objective Investigating whether visible nigrosomes in PD patients differ from those of healthy subjects (HC). Methods Forty‐eight PD and 35 HC underwent 3 T‐
Maria Eugenia Caligiuri +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham +8 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse +224 more
wiley +1 more source